US › Healthcare

DiaMedica Therapeutics Inc (DMAC)

US · Healthcare · Biotechnology

$6.54+0.31%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-10.0M
Profit YoY
-30.3%
EPS
$-0.19
EPS estimate
$-0.18

EPS came in at -0.19 against a street estimate of -0.18 — a miss of 5.6%.

Key statistics

Market cap
$351.3M
Forward P/E
0.0
P/B
7.22
Book value
$0.88
EPS (TTM)
$-0.71
52-week high
$10.42
52-week low
$4.39
50-day MA
$6.50
200-day MA
$7.20
Beta
0.97

Analyst view

Analysts rate DiaMedica Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $15.50.

Shareholding

Insiders
27.74%
Institutions
37.93%

Largest institutional holders

FundStake
Cooperman Leon G3.75%
BlackRock Inc3.44%
Millennium Management LLC1.74%
PARAGON Assoc & PARAGON Assoc II JV1.62%
Geode Capital Management, LLC1.45%
Vanguard Group Inc1.34%
State Street Corp1.20%
First Manhattan Co. LLC0.84%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for DiaMedica Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.